Since childhood relapsed ALL is a rare disease, international collaboration is needed to recruit enough patients for studying standard and innovative treatment strategies within this specific patient group. The IntReALL 2010 Consortium builds collaboration between 20 national study groups including the relevant groups from Europe and selected non-European countries.
The IntReALL2010 consortium represents all relevant European Study Groups plus selected groups from other continents with large experience in treating children with relapsed/refractory acute lymphoblastic leukaemia.
The following clinical study groups are represented in the IntReALL 2010 Consortium:
The ALL-REZ BFM Study group including Germany, Austria, the German speaking part of Switzerland and the Czech Republic,
The COPRALL Study Group, including France, Belgium, Luxembourg, and Portugal,
The NOPHO Study Group represents all Scandinavian countries (Denmark, Finland, Iceland, Norway, Sweden).
The UKALL Relapse Study Group conducting the ALL R3 trial including the UK, Ireland, the Netherlands, Australia and New Zealand,
The AIEOP group on relapsed ALL coordinates the clinical and research activities on children with relapsed ALL in Italy.
The IntReALL Consortium is supported by scientific institutions organizing and performing elementary aspects of an international clinical trial. Integration of parents into the design, planning and conduction of a clinical trial on children with cancer is an essential factor for the broad acceptance and the compliance to the study. Every country, mostly even every city has its own parent organization supporting the local paediatric oncology centres. CCI (formerly ICCCPO) provides a worldwide network of parent organizations.
Activities and expertise in translational science and biology
The clinical studies require a systematic collection and storage of patient material, in first line to confirm the correct diagnosis and the correct risk stratification, in second line to organize a program on biologic investigations with the aim to investigate the pathogenetic and biologic features of the disease and to discover new risk factors and biologic rationales for new treatment strategies.
Partners' collaboration in IntReALL see >> here